Latest news

• Novartis raises 2019 guidance as new products gather speed

  Vas Narasimhan. In the second quarter Sandoz sales were up 3% to $2.4bn, with double-digit gains in Europe for its trio of biosimilars - Rixathon (rituximab), Hyrimoz (adalimumab) and Erelzi

• Alcon spun off, leaner Novartis raises profit forecast

  Despite discussions of a possible sell-off, Sandoz’s biosimilars division is performing well, with double digit growth in Europe thanks to products such as Rixathon (rituximab), Hyrimoz (adalimumab) and Erelzi

• Novartis follows Pfizer and freezes US prices this year

  Erelzi(etanercept) in the EU, and Zarxio (filgrastim) in the US.

• Novartis doubles down on biosimilars with Biocon alliance

  In the last couple of years it has picked up approvals for Rixathon - a biosimilar of Roche’s cancer and arthritis drug MabThera (rituximab) - as well as its Erelzi version of

• Alcon's return to growth gives Novartis 'options', says CEO

  Novartis said the recent approval and launch of two biosimilar drugs in the EU - Erelzi (etanercept) to treat immunological diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis and Rixathon (rituximab)